Reports
Sale
Global Acromegaly Treatment Market Share, Size, Forecast: By Diagnosis Type: GH and IGF-I Measurement, Growth Hormone Suppression Test, Others; By Treatment Type; By Diseases Type; By Route of Administration; By Treatment Centers; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Acromegaly Treatment Market Outlook
The global acromegaly treatment market size attained a value of USD 1.73 billion in 2023. The market is likely to witness further growth at a CAGR of 7.7% during the forecast period of 2024-2032 to attain a value of approximately USD 3.36 billion by 2032. The growth of the market can be attributed to the rising awareness about the disorder among healthcare professionals and patients.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is Expected to Lead the Market for Acromegaly Treatment
North America, owing to the high demand for novel prescriptions, innovative products, and the presence of established players in the market, is expected to be the leading region for acromegaly treatment. The United States and Canada are the largest markets for acromegaly treatment; due to the growing population prevalence of the disease, the medical institutes are spreading awareness of treatments with the government introducing favourable policies. Furthermore, the rise in collaborations and effort in research and development by the established organisations to develop new products and innovative procedures are propelling the demand for treatment, which in turn, helps in market growth.
Asia Pacific is Proliferating with the Increased Funding for Healthcare
Asia Pacific is showing promising growth opportunities for the market. The region is going through industrialisation, and people are increasingly moving to urban areas seeking a better lifestyle, which shows the rising awareness among people. The government is increasing their healthcare expenditure to establish an improved infrastructure, and with development in various sectors, the spending power of people will simultaneously increase, which will further drive the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentations
Acromegaly is a hormonal disorder that develops in the pituitary gland, which increases growth hormone production. A non-cancerous tumour usually causes it. In acromegaly treatment, the goal is to restore the pituitary gland to function normally and produce normal levels of growth hormone.
By product, the market for acromegaly treatment includes:
- Somatostatin Analogs (SSA)
- Growth Hormone Receptor Antagonist (GHRA)
- Others
The end-uses of the acromegaly treatment include:
- Hospitals
- Clinics
- Others
The regional markets for acromegaly treatment can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa, with North America leading the market and Asia Pacific being the fastest-growing region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Diseases and New Medications Bolstering the Market Growth
As the population rises, the number of patients is increasing, and to provide safe and sufficient services, and the healthcare infrastructure is being developed continuously. Advancements in surgery and innovative alternate techniques are further broadening the market limits. The high cost of surgery can pose a little setback to market growth. However, governments are introducing favourable policies to spread medical treatment awareness. Multiple medical institutes and organisations are focusing on research and development to introduce novel medications, such as somatostatin analogs, which help stop the excess production of growth hormones. Additionally, with the launch of technologically advanced detection techniques like radiosurgery, radio imaging technologies provide cost-effective options for diagnosis with minimum side effects.
Key Players in the Global Market for Acromegaly Treatment
The report gives a detailed analysis of the following key players in the global acromegaly treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, investments, expansions of capacity, and plant turnarounds:
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline plc.
- Novartis AG
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Johnson & Johnson Private Limited
- Hikma Pharmaceuticals PLC.
- Bristol-Myers Squibb Company
- Bayer AG
- Boehringer Ingelheim International GmbH.
- Dr. Reddy's Laboratories Ltd.
- Gilead Sciences, Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Lupin
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diseases Type |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Centers |
|
| Breakup by Treatment Channel |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Acromegaly Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Acromegaly Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Acromegaly Epidemiology (2016-2031)
5.3 Europe Acromegaly Epidemiology (2016-2031)
5.4 Asia-Pacific Acromegaly Epidemiology (2016-2031)
5.5 Latin America Acromegaly Epidemiology (2016-2031)
5.6 Middle East & Africa Acromegaly Epidemiology (2016-2031)
6 Global Acromegaly Treatment Market Overview
6.1 Global Acromegaly Treatment Market Historical Value (2017-2023)
6.2 Global Acromegaly Treatment Market Forecast Value (2024-2032)
7 Global Acromegaly Treatment Market Landscape
7.1 Acromegaly Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cardiovascular Drugs Product Landscape
7.2.1 Analysis by Diagnosis Type
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Acromegaly Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Acromegaly Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Acromegaly Treatment Market Segmentation
11.1 Global Acromegaly Treatment Market by Diagnosis Type
11.1.1 Market Overview
11.1.2 GH and IGF-I Measurement
11.1.3 Growth Hormone Suppression Test
11.1.4 Imaging
11.1.4.1 Spine x-ray
11.1.4.2 MRI of the brain, including the pituitary gland
11.1.4.3 Echocardiogram
11.1.4.4 Colonoscopy
11.1.4.5 Others
11.1.5 Others
11.2 Global Acromegaly Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Medication
11.2.2.1 Somatostatin analogues
11.2.2.2 Dopamine agonists
11.2.2.3 Growth hormone antagonist
11.2.2.4 Others
11.2.3 Radiation Therapy
11.2.4 Surgery
11.2.5 Others
11.3 Global Acromegaly Treatment Market by Diseases Type
11.3.1 Ectopic Acromegaly
11.3.2 Acromegaly Due to Growth Hormone
11.4 Global Acromegaly Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parentals
11.4.4 Others
11.5 Global Acromegaly Treatment Market by Treatment Centers
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Rehabilitation Centers
11.5.6 Others
11.6 Global Acromegaly Treatment Market by Treatment Channel
11.6.1 Market Overview
11.6.2 Public
11.6.3 Private
11.7 Global Acromegaly Treatment Market by Distribution Channel
11.7.1 Market Overview
11.7.2 Hospital Pharmacy
11.7.3 Retail Pharmacy
11.7.4 Online Pharmacy
11.7.5 Others
11.8 Global Acromegaly Treatment Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.3 Europe
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Acromegaly Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Acromegaly Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Acromegaly Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Acromegaly Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Acromegaly Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Mylan N.V.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Teva Pharmaceutical Industries Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline plc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Allergan
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AstraZeneca
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Johnson & Johnson Private Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Hikma Pharmaceuticals PLC.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Bristol-Myers Squibb Company
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Bayer AG
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Boehringer Ingelheim International GmbH.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Dr. Reddy's Laboratories Ltd.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Gilead Sciences, Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Eli Lilly and Company
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 AbbVie Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Lupin
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Acromegaly Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for acromegaly treatment attained a value of nearly USD 1.73 billion.
The market is projected to grow at a CAGR of 7.7% between 2024 and 2032.
The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach USD 3.36 billion by 2032.
The increasing prevalence of diseases among the growing population, technological advancements, and increasing investment in healthcare are the major industry drivers.
The players' key industry trends are technological advancements and favourable government policies to reduce treatment expenses.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America being the leading region in the market and Asia Pacific growing at an exponential rate.
The different products in the market include somatostatin analogs (SSA) and growth hormone receptor antagonist (GHRA), among others.
The end-users for acromegaly treatment in the market include Hospitals and Clinics, among others.
The major players in the industry are Novartis AG, Ipsen Biopharmaceuticals, Inc., Chiasma, Inc., Pfizer Inc., and Ionis Pharmaceuticals, Inc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER